Medtronic

Symplicity Spyral[™]

multi electrode renal denervation system


One catheter size, easy-to-use design

The Symplicity Spyral™ multi-electrode renal denervation catheter offers an easy-to-use, plug-and-play design. One catheter size fits vessels 3-8 mm in diameter, enabling access to the main renal artery, accessory, and branch vessels during the Symplicity[™] blood pressure procedure. The multi-electrode, helical design covers four quadrants simultaneously for a circumferential ablation to maximize the probability of a complete denervation.^{1,2}

Proven to deliver significant, safe, and sustained blood pressure reductions³⁻⁵

As part of the Symplicity Spyral[™] renal denervation system, the Symplicity Spyral catheter supplies precisely controlled and targeted radiofrequency (RF) energy to the renal nerves to safely disrupt overactive sympathetic signaling between the kidneys and brain.1

- Distal self-expanding array of four electrodes
- Tracks over a 0.014" guidewire
- Unique electrode pattern separates ablation zones and preserves vascular function
- Non-occlusive catheter design allows for continuous blood flow to protect the vessel wall¹



Components



- Catheter: 4F catheter, tompatible with 6F guide catheter, 0.014" guidewire
- Electrodes: 4 RF monopolar, gold, radio-opaque, 1.5 mm length
- Thermocouple: T-type
- Tip marker: platinum/iridium alloy
- Handle: injection molded
- Integrated extension cable for connection with the Symplicity $G3^{\mathsf{TM}}$ renal denervation RF generator

Materials

Handle

 ABS, thermoplastic elastomer overmold

Thermocouple

• T-type

Catheter - RDN016

- Proximal shaft: polyether block amide laminated over stainless steel
- Intermediate tubing: polyether block amide with braided stainless steel
- Distal electrode array jacket: thermoplastic urethane
- Tip: thermoplastic
- Guidewire lumen: high-density polyethylene liner
- Spiral shaping element: nickel/titanium
- Guidewire loading tool: thermoplastic

Not present

- Latex
- Phthalate

Size

- 117 cm working length-compatible with 90 cm or shorter guide catheters
- 55 cm length is recommended; 90 cm max length
- 0.052" OD[†]

Technical Specs

- Rapid exchange design compatible with 0.014" guidewire
- Guidewire retraction used to deploy the spiral electrode array
- RX joint: 30 cm from distal tip
- Vessel diameter treatment range: 3-8 mm
- Four independently controlled RF monopolar gold electrodes, spaced ~6.5 mm apart
- Treatment length: 17-21 mm if all electrodes are activated
- Tip length: ~5 mm
- Tip marker: 1 mm proximal of distal tip
- Femoral shaft marker: 55 cm from distal tip

Sterilisation process

E-beam and 10⁻⁶ SAL

Shelf life

Three years

 $For a \ listing \ of indications, contraindications, precautions, warnings, and potential \ adverse \ events, please \ refer to the lnstructions for Use.$

medtronic.ca

©2024 Medtronic. All rights reserved. Medtronic, Medtronic logo and Engineering the extraordinary are trademarks of Medtronic. **Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company. IJC202404491FC CA-CTI-0315-F Rev. 03/2024



 $^{^{\}dagger}$ Catheter dimension of 0.052" is average maximum diameter determined during design verification. Upper bound allowable is 0.061".

¹ Coates P, Tunev S, Trudel J, Hettrick DA. Time, Temperature, Power, and Impedance Considerations for Radiofrequency Catheter Renal Denervation. *Cardiovasc Revasc Med*. September 2022;42:171-177.

² Medtronic Symplicity Spyral™ Instructions for Use.

³ Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. *Lancet*. May 2, 2020;395(10234):1444-1451.

⁴ Mahfoud F, Kandzari DE, Kario K, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. *Lancet*. April 9, 2022;399(10234):1401-1410.

⁵ Mahfoud F, Mancia G, Schmieder R, et al. Three-year safety and efficacy in the Global Symplicity Registry: Impact of antihypertensive medication burden on blood pressure reduction. Presented at PCR e-course; 2020.